Norman R.C. Campbell

Last updated

Norman R.C. Campbell is a Professor Emeritus of the University of Calgary, where he served as professor of Medicine, Community Health Sciences and Physiology and Pharmacology and as a member of the O'Brien Institute for Public Health and Libin Cardiovascular Institute of Alberta. Dr Campbell continues as a Senior consultant to Resolve To Save Lives (RTSL), a temporary advisor to the World Bank to provide advice for hypertension control in Samoa and Cambodia, a consultant to the Pan American Health Organization Hearts in the Americas Initiative and a consultant to the for hypertension control in Mongolia.

In the past, Dr Campbell has been

• President of the World Hypertension League (2013-2015; League of national hypertension and cardiovascular organizations dedicated to global hypertension prevention and control).

• President of Blood Pressure Canada, (1996-1999 and 2006-2010).

• President of the Canadian Hypertension Society (1999-2000).

• Founder and Chair of the annual Canadian hypertension recommendations/control program 2000-2002, 2005-2010 (Canadian Hypertension Education Program).

• President of the Canadian Society for Clinical Pharmacology and Therapeutics

• Chair of the Pan American Health Organization / World Health Organization Regional Expert Group on Cardiovascular Disease Prevention through Dietary Salt Reduction (2009-2011).

• Co-Chair of the Pan American Health Organization / World Health Organization Technical Advisory Group on Cardiovascular Disease Prevention through Dietary Salt Reduction (2012-2015).

•Chair of the Pan American Health Organization Regional Expert Group for cardiovascular disease prevention through population-wide dietary salt reduction.

• Chair and Co-chair of the Vascular Risk Reduction program of the Alberta Health Services Strategic Clinical Networks (2012-2016),

• Chair and Co-Chair of the ACTION network of Alberta Health Care Professional and Scientific Organizations to reduce the burden of cardiovascular disease (2013-2017)][http://Chair%20and%20Co-Chair%20of%20the%20ACTION%20network%20of%20Alberta%20Health%20Care%20Professional%20and%20Scientific%20https://www.albertahealthservices.ca/scns/page10585.aspx%20ACTION%20Network

• Founder and Chair of the ‘TRUE’ international consortium of health and scientific organizations to develop standards for the conduct of clinical research on dietary salt .

• Founder and initial Chair ‘Science of salt’ weekly review of the literature on dietary sodium and regular systematic critical appraisals of clinical research relating to the harms of dietary sodium and methods to reduce dietary salt.

• Founder and Chair of the Canadian Hypertension Advisory Committee (2011-2016). Vice chair 2016-2019

• HSF CIHR Chair in Hypertension Prevention and Control (2011-2016).

• CHIR Canada Chair in Hypertension Prevention and Control (2006-2011).

• Chair and Co-Chair of the integration committee to form Hypertension Canada from the Canadian Hypertension Society, Blood Pressure Canada and Canadian Hypertension Education Program.

During the tenure as Presidents of Blood Pressure Canada and the Canadian Hypertension Society, Dr Campbell led several strategic planning sessions and initiated the annual Canadian Hypertension Recommendations - Control program in 2000 developing the annually updated evidence-based recommendations process, a separate implementation process and a monitoring and evaluation process. The program was associated with a more than 5-fold increase in control of hypertension in Canada (13% to 68%; 1985-1992 to 2012-13). In Blood Pressure Canada, Dr Campbell led the development in 2006 of a national advocacy and education program for dietary sodium reduction and a national public education program for hypertension. Dr Campbell as President of the Canadian Society for Clinical Pharmacology (2002-2004) led the organization in two strategic planning sessions, hosting an international meeting to celebrate the 25th anniversary of the organization and creating the annual Canadian Therapeutic Congress with the meeting of three national pharmacology and therapeutics organizations. In 2010-2011, Dr Campbell chaired the development of a Pan Canadian Framework for hypertension prevention and control, in 2014-15, the 5-year update of the Framework and was also on the 1999 Canadian hypertension strategic planning committee. Dr Campbell was on the steering committee and co-chaired the Risk Factor committee for the Canadian Heart Health Strategy 2007-9 and was on the executive of the Health Canada Intersectoral Sodium Reduction Committee and a member of its four subcommittees (2007-2010). Dr Campbell chaired the Pan American Health Organization / World Health Organization Regional Expert Group on Cardiovascular Disease Prevention through Dietary Salt Reduction that had the task of making policy recommendations to reduce dietary sodium in the America’s (2009-2011) and co-chaired the technical advisory group (TAG) of the Pan American Health Organization / World Health Organization Region effort on the same topic 2012-2015. The number of countries in the America’s with national salt reduction programs increased from 3 to over 20 during this time frame with several countries developing world leading interventions. In 2010-2011, Dr. Campbell was a member of the WHO Nutrition Guidance Expert Advisory Group (micronutrient subcommittee). In addition, Dr Campbell chaired and then co-chaired the committee to integrate the Canadian Hypertension Society, Blood Pressure Canada and the Canadian Hypertension Education Program into Hypertension Canada in 2009-2010. Dr Campbell is a past chair of the Alberta, Ministers Expert Committee on Drugs and Therapeutics (2002-2004) and is a former Head (1994-2000) and Chief of General Medicine (1994-1999) at the University of Calgary and the Calgary Health Region. During Dr Campbells tenure as president, the World Hypertension League increased the number of member associations by 40, developed regional offices, official relations with the Journal of Clinical Hypertension, global recognition awards for prevention and control of hypertension, a needs assessment of national hypertension organizations, global fact sheets and calls to action on hypertension and on dietary salt, a fact sheet and call to action on hypertension in Africa, a training module for blood pressure screening programs, multiple position statements relating to dietary salt, standards for assessment of blood pressure, launched a new website and oversaw the development of a process for weekly updated systematic literature reviews on how to reduce dietary salt and the health impacts of reducing dietary salt with a periodic critical appraisals of the literature on both salt topics. More recently Dr Campbell lead the development of global calls to action on dietary salt (supported by 74 national and international organizations) and on hypertension control (supported by 40 national and international organizations). 

He is well known for his work with sodium reduction around the world. He has over 550 publications in peer-reviewed journals and has received several recognitions for his efforts. [1]

Campbell obtained an MD degree from Memorial University of Newfoundland where he also completed his Internal Medicine residency. He has provided more than 500 invited national and international presentations.{https://contacts.ucalgary.ca/info/dmed/profiles/1-4839961, 2023}</ref>

Recognitions and awards


Related Research Articles

<span class="mw-page-title-main">Hypertension</span> Long-term high blood pressure in the arteries

Hypertension, also known as high blood pressure, is a long-term medical condition in which the blood pressure in the arteries is persistently elevated. High blood pressure usually does not cause symptoms. It is, however, a major risk factor for stroke, coronary artery disease, heart failure, atrial fibrillation, peripheral arterial disease, vision loss, chronic kidney disease, and dementia. Hypertension is a major cause of premature death worldwide.

<span class="mw-page-title-main">Cardiovascular disease</span> Class of diseases that involve the heart or blood vessels

Cardiovascular disease (CVD) is any disease involving the heart or blood vessels. CVDs constitute a class of diseases that includes: coronary artery diseases, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, abnormal heart rhythms, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.

Essential hypertension is the form of hypertension that by definition has no identifiable secondary cause. It is the most common type affecting 85% of those with high blood pressure. The remaining 15% is accounted for by various causes of secondary hypertension. Primary hypertension tends to be familial and is likely to be the consequence of an interaction between environmental and genetic factors. Prevalence of essential hypertension increases with age, and individuals with relatively high blood pressure at younger ages are at increased risk for the subsequent development of hypertension. Hypertension can increase the risk of cerebral, cardiac, and renal events.

<span class="mw-page-title-main">Chlortalidone</span> Thiazide-like diuretic drug

Chlortalidone, also known as chlorthalidone, is a thiazide-like diuretic drug used to treat high blood pressure, swelling, diabetes insipidus, and renal tubular acidosis. Because chlortalidone is reliably effective in most patients with high blood pressure, it is considered a preferred initial treatment. It is also used to prevent calcium-based kidney stones. It is taken by mouth. Effects generally begin within three hours and last for up to three days. Long-term treatment with chlortalidone is more effective than hydrochlorothiazide for prevention of heart attack or stroke.

<span class="mw-page-title-main">Thiazide</span> Class of chemical compounds

Thiazide refers to both a class of sulfur-containing organic molecules and a class of diuretics based on the chemical structure of benzothiadiazine. The thiazide drug class was discovered and developed at Merck and Co. in the 1950s. The first approved drug of this class, chlorothiazide, was marketed under the trade name Diuril beginning in 1958. In most countries, thiazides are the least expensive antihypertensive drugs available.

The DASH diet is a dietary pattern promoted by the U.S.-based National Heart, Lung, and Blood Institute to prevent and control hypertension. The DASH diet is rich in fruits, vegetables, whole grains, and low-fat dairy foods. It includes meat, fish, poultry, nuts, and beans, and is limited in sugar-sweetened foods and beverages, red meat, and added fats. In addition to its effect on blood pressure, it is designed to be a well-balanced approach to eating for the general public. DASH is recommended by the United States Department of Agriculture (USDA) as a healthy eating plan. The DASH diet is one of three healthy diets recommended in the 2015–2020 US Dietary Guidelines, which also include the Mediterranean diet and a vegetarian diet. The American Heart Association (AHA) considers the DASH diet "specific and well-documented across age, sex and ethnically diverse groups."

A low sodium diet is a diet that includes no more than 1,500 to 2,400 mg of sodium per day.

On October 25, 2007, the Minister of Health announced that the Government of Canada would establish an expert Sodium Working Group to explore options for reducing sodium intake and cardiovascular disease among Canadians.

Canadian health claims by Health Canada, the department of the Government of Canada responsible for national health, has allowed five scientifically verified disease risk reduction claims to be used on food labels and on food advertising. Other countries, including the United States and Great Britain, have approved similar health claims on food labels.

<span class="mw-page-title-main">Salt and cardiovascular disease</span> Association between salt consumption and cardiovascular disease

Salt consumption has been extensively studied for its role in human physiology and impact on human health. Chronic, high intake of dietary salt consumption is associated with hypertension and cardiovascular disease, in addition to other adverse health outcomes. Major health and scientific organizations, such as the World Health Organization, US Centers for Disease Control and Prevention, and American Heart Association, have established high salt consumption as a major risk factor for cardiovascular diseases and stroke.

Donald Robert James Singer was a British clinical pharmacologist who was the president of the Fellowship of Postgraduate Medicine.

John David Spence is a Canadian medical doctor, medical researcher and Professor Emeritus at the University of Western Ontario. He is affiliated with the University of Western Ontario and the Robarts Research Institute, one of Canada's leading medical research organizations. Before his retirement from clinical practice in July 2022, he was also affiliated with the London Health Sciences Centre's University Hospital. He is a recognized expert in stroke prevention and stroke prevention research, with more than 600 peer-reviewed publications since 1970. He delivered more than 600 lectures on stroke prevention in 42 countries. In 2015, he received the Research Excellence Award from the Canadian Society for Atherosclerosis, Thrombosis and Vascular Biology. In 2019, he was appointed a Member of the Order of Canada, and in 2020 he received the William Feinberg Award from the American Heart Association for excellence in clinical stroke research.

<span class="mw-page-title-main">Health effects of salt</span> Conditions associated with the consumption of either too much or too little salt

The health effects of salt are the conditions associated with the consumption of either too much or too little salt. Salt is a mineral composed primarily of sodium chloride (NaCl) and is used in food for both preservation and flavor. Sodium ions are needed in small quantities by most living things, as are chloride ions. Salt is involved in regulating the water content of the body. The sodium ion itself is used for electrical signaling in the nervous system.

Professor Peter Sleight M.D.(Cantab.), D.M. (Oxon.) FRCP FACC was a distinguished and internationally renowned research cardiologist and an Honorary Consultant Physician at the John Radcliffe Hospital in Oxford and the Oxford University Hospitals NHS Foundation Trust. Sleight was Emeritus Field Marshal Alexander Professor of Cardiovascular Medicine at the University of Oxford and an Emeritus Fellow of Exeter College, Oxford.

Salim Yusuf is an Indian-born Canadian physician, the Marion W. Burke Chair in Cardiovascular Disease at McMaster University Medical School. He is a cardiologist and epidemiologist.

Hypertension is managed using lifestyle modification and antihypertensive medications. Hypertension is usually treated to achieve a blood pressure of below 140/90 mmHg to 160/100 mmHg. According to one 2003 review, reduction of the blood pressure by 5 mmHg can decrease the risk of stroke by 34% and of ischaemic heart disease by 21% and reduce the likelihood of dementia, heart failure, and mortality from cardiovascular disease.

Rhian M. Touyz Koppel MBBCh, MSc (Med), PhD, FRCP, FRSE, FMedSci, FCAHS is a Canadian medical researcher. She is currently serving as the Executive Director and Chief Scientific Officer of the Research Institute of the McGill University Health Centre in Montreal, Canada, since 2021. A clinician scientist, her research primarily focuses on hypertension and cardiovascular disease.

<span class="mw-page-title-main">Harriet P. Dustan</span> American physician

Harriet Pearson Dustan (1920–1999) was an American physician who is known for her pioneering contributions to effective detection and treatment of hypertension. She was the first woman to serve on the Board of Governors of the American Board of Internal Medicine.

Cheryl Ann Marie Anderson is an American epidemiologist. Anderson is a professor at and founding Dean of the University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science. Anderson's research focus is on nutrition and chronic disease prevention in under-served human populations.

A non-pharmaceutical intervention or non-pharmacological intervention (NPI) is any type of health intervention which is not primarily based on medication. Some examples include exercise, sleep improvement, or dietary habits.

References

  1. ↑ {https://contacts.ucalgary.ca/info/dmed/profiles/1-4839961, 2023}
  2. 1 2 3 4 5 6 7 8 "Is For Sale". Hypertensiontalk.com. Retrieved 2022-05-02.
  3. ↑ "The Governor General of Canada".
  4. ↑ "2015 CMA Award recipients". Archived from the original on 2015-10-23. Retrieved 2016-03-06.
  5. ↑ "Honorary degrees to be awarded during spring convocation ceremonies". Memorial University of Newfoundland - News Release. Ref # 53. 9 April 2019. Retrieved 7 March 2021.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.